来氟米特治疗类风湿性关节炎50例  

Leflunomide in the Treatment of 50 Cases of Rheumatoid Arthritis

作　　者：冯洪江[1] 许小军[1] 田再泉[2] 邓长泉[1] 

机构地区：[1]山东省聊城市人民医院药剂科,252000 [2]山东省聊城市人民医院内科,252000

出　　处：《医药导报》2006年第9期914-916,共3页Herald of Medicine

摘　　要：目的探讨新型抗炎免疫抑制药来氟米特治疗活动期类风湿关节炎(RA)的疗效及安全性。方法采用随机、单盲对照方法。选择疾病活动期RA患者95例,分为治疗组50例,给予来氟米特20 mg.d-1,qd,po;对照组40例,给予甲氨蝶呤15 mg,每周1次,po。12周为1个疗程。结果两组患者的症状、体征及实验室指标均显著改善。治疗组与对照组12周末总有效率分别为90.0%,95.6%(P>0.05)。两组各有7例发生不良反应,不良反应发生率分别为14.0%,15.6%(P>0.05),但治疗组不良反应程度轻,患者耐受性好。结论来氟米特对RA患者有良好的治疗作用,且不良反应小。Objective To compare the effectiveness and safety of leflunomide （LEF） with those of methotrexate （MTX） in patients with active rheumatoid arthritis （RA）. Methods Ninty-five patients were randomly assigned to receive LEF or MTX. The patients in the treatment group received LEF 20 mg·d^-1, and those in the control group received MTX 15 mg week, totally 12 weeks as a course of treatment. Results The total effective rates of the treatment group and the control group were 90.0% （n = 50） and 95.6% （n = 45） respectively. There was no significant difference between the two groups in the effectiveness （P 〉 0.05）. The adverse reaction rate was 14.0% （7 case） in the treatment group and 15.6% （7 case） in the control group with no significant difference between the two groups （P 〉 0.05）. But the adverse reactions were more tolerable in treatment group than those in control group. Conclusion This study suggests that LEF is an effective drug with minor adverse reactions for active rheumatoid arthritis.

关 键 词：来氟米特 甲氨蝶呤 关节炎 类风湿性 

分 类 号：R979.5[医药卫生—药品] R593.22[医药卫生—药学]